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 1. Executive Summary 
 
Shear stress-sensitive nanoparticles are a promising new field for drug delivery. This            
novel method may allow the targeted release of drugs such as statins or vasodilators to areas of                 
high shear in the bloodstream, as occurs near a stenosis. Previous work claims that shear               
stress-sensitive nanoparticles may deliver a targeted release of clot-busting or          
cholesterol-fighting drugs to arterial plaque [1]. However, these studies have only examined  flow             
characteristics near plaques and have not considered the movement of nanoparticles within these             
flows or the complex process of drug diffusion from the particle’s shear location into the plaque.                
The study outlined here considers the entire process from nanoparticle entry upstream of the              
plaque through drug diffusion into the tissue. 
A right coronary artery with a Type I plaque morphology was designed using the 3D               
CAD design software SolidWorksⓇ. COMSOL MultiphysicsⓇ, a commercially available         
modeling software, was used to model blood flow past this plaque with a varying inlet velocity                
to simulate pulsatile flow. Particle diffusion through the blood and subsequent drug diffusion into              
the tissue were simulated. Average dimensional values and flow velocities for men were used              
since they are more at risk for developing atherosclerosis. 
The results of these simulations showed that the plaque buildup at 35% stenosis causes              
sufficient shear stress to break the nanoparticles, releasing the drug into the blood. Most drug,               
once it was released from the nanoparticles, was found to diffuse into the downstream half of the                 
plaque. Moreover, it was found that the optimal breaking shear stress of the nanoparticles for               
targeted drug delivery to the stenosis was nearly the maximum shear stress achieved in the flow                
at 75 Pa, while the optimal infusion concentration is close to the maximum clinically allowable               
at 0.045 mol/m 3  [2]. 
This computational study has filled an important void in the body of research on this               
novel drug delivery method. It has verified the rupture of nanoparticles under 35% stenotic              
conditions while showing subsequent drug diffusion patterns, which suggests that this method            
may not be suited for targeting drug delivery to arterial plaques. Further research should examine               
the effects of arterial wall compliance, consider non-Newtonian blood flow, and test realistic             
plaque geometries obtained, for example, via intravascular ultrasound (IVUS). Though shear           
stress-sensitive nanoparticle drug delivery may not ideally target drug to arterial stenoses, this             
novel method may prove useful for modeling tumorigenic systems, where fluid shear stress has              
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 2. Introduction 
Coronary artery disease (CAD) is the most common type of heart disease with more than               
3 million cases and over 370,000 deaths annually [3]. The main cause of CAD is atherosclerosis,                
or plaque buildup along the walls of the artery [4]. If caught in time, atherosclerosis can be                 
treated by percutaneous revascularization (stent placement) to reopen arteries, beta blockers to            
lower blood pressure, nitroglycerin to dilate vessels, and a class of drugs called statins to lower                
blood cholesterol levels [5]. However, all these treatments have risks and side effects.             
Nitroglycerin can cause headaches, sweating, and dizziness, while statins can cause various and             
significant side effects such as muscle pain, liver damage, increased risk of type II diabetes               
mellitus, memory loss, and confusion [5-6]. In an attempt to mitigate these side-effects, various              
targeted treatments are being developed that aim to minimize drug diffusion to non-affected             
areas. 
Nanoparticles have become an increasingly popular tool in multiple disciplines because           
of their versatility, size, and uniformity, and recent research focus has yielded an abundance of               
new methods and uses [7]. A few recent studies have investigated nanoparticle use in              
cardiovascular disease, specifically in delivering targeted drug treatment to plaque-prone areas           
[1,7,8]. The results seem promising but as in any study, there is a need for future research and                  
validation. The proposed technique involves fabricating nanoparticles that are sensitive to the            
higher-than-normal shear stresses in blood flow around arterial plaques as shown in Figure 1.              
Given the diversity of the human vascular system and the complex interplay between blood flow               
and drug diffusion, it has yet to be determined whether this technique is as robust as it seems.                  
Specifically, high flow velocities in arteries could cause rapid washout of drug after release from               
the nanoparticles, causing statins or other drugs to diffuse into downstream tissue where they              
may elicit some combination of the side effects listed above. 
As noted above, there are many drugs used to treat coronary artery disease. Each of the                
three main types listed above (beta blockers, statins, nitroglycerin) has a different target. In              
particular, beta blockers and statins are most effective when delivered to the entire circulatory              
system while nitroglycerin need only be delivered to the affected areas. To understand why, it is                
important to know how nitroglycerin operates. In the blood, nitroglycerin is rapidly converted to              
nitric oxide which acts as a non-selective vasodilator, diffusing into the vessel wall and causing               
relaxation of the arterial smooth muscle layer found in the tunica media, resulting in vessel               
widening (see Figure 2). The vessel-widening action of nitroglycerin is, in effect, the reverse              
process of coronary artery disease where plaque buildup causes vessel narrowing and limits             
blood flow downstream. Therefore, it need only target areas where vessels have become             
constricted due to plaque buildup. In fact, nitroglycerin would  ideally only target those vessels,              
as its non-selective vasodilatory effects are the cause of many of the side effects associated with                
the drug. 
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Figure 1:  Proposed method for targeted drug delivery to arterial stenoses using shear             
stress-sensitive nanoparticles. Shown is an axial cross-section of a vessel with plaque buildup,             
colored tan, nanoparticles as white capsules, and drug as yellow dots. Darker red-purple blood              
signifies high shear stress and nanoparticles in this region have ruptured, releasing drug. 
 
Computational studies are playing an increasing role in the research process for a variety              
of reasons. The time and cost-effectiveness of simulated studies is significant compared to             
physical prototyping and experimentation. This allows broader access to the engineering process            
given the ubiquity of sufficient computing power. Furthermore, computational studies are           
inherently more adaptable and iterable than their counterparts, and testing or examining different             
sets of parameters does not require buying a whole new suite of testing or imaging equipment.                
Compared to analytical solutions of modeled systems, numerical solutions are more flexible and             
nuanced than often oversimplified analytical methods. COMSOL Multiphysics®, is a          
widely-used general-purpose modeling software that can simulate a variety of physical systems            
including but not limited to: fluid flow, mass transport, heat transfer, solid mechanics, and              
electrostatics. 
This study uses COMSOL to examine the sensitivity of shear-induced nanoparticle drug            
delivery for treatment of CAD. A focus was placed on parts of the process that have yet to be                   
investigated, such as the process of drug diffusion after release from nanoparticles, and             






4 of 26 
 2.1 Problem Statement 
 
The purpose of this study is to determine whether shear stress-induced nanoparticle drug             
delivery is an effective method for treatment of coronary artery disease. Non-specific delivery of              
nitroglycerin can lead to a number of side-effects such as dizziness, severe headaches, chest pain,               
and anaphylaxis in severe cases. As such, it is necessary to model the shear and velocity profiles                 
of nanoparticles and drug in the artery to ensure that a shear stress dependent delivery system is                 
targeted and precise. Additionally, it is important to measure the effects of parameters such as               
critical nanoparticle shear stress, nanoparticle inlet concentration, and drug diffusivity on such a             
system. 
 
2.2 Design Objectives 
 
The goals for this project are as follows: 
1. Model the shear profile in a typical adult male right coronary artery with 35% stenosis by                
simulating blood flow under physiological conditions. 
2. Determine the effects of pathological blood flow on nanoparticle diffusion. 
3. Visualize subsequent effects on diffusion of nitroglycerin through the blood and vessel            
tissue. 
4. Determine the sensitivity of nitroglycerin delivery to treatment design parameters 





A 2D geometric model was created in SolidWorksⓇ. This geometry was imported into in              
COMSOL Multiphysics ® to create a 2D axisymmetric model  that simulates blood flow through             
the right coronary artery. The model approximates the geometry of the artery as concentric              
cylinders, as shown in Figure 2, with the following layers: tunica adventitia, tunica media, tunica               
intima, and plaque.  Plaque dimensions were constructed based on the average morphology            
obtained from intravascular ultrasound. In order to determine whether flow past an arterial             
plaque would cause proper drug release from the shear-sensitive nanoparticles, the flow            
characteristics in a simplified coronary artery were modeled. The plaque, tunica adventitia,            
tunica media, and tunica intima were assumed to have identical physical properties.  
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 Figure 2 : Schematic of the right coronary artery and its location in the heart. The right                
coronary artery geometry was simplified to an axisymmetric cylinder for ease of computation.             
The type I plaque can be seen on the inner vessel wall. Heart cartoon courtesy of Blausen.com. 
 
The four most common plaque morphologies, based on a study of 42 patients with Coronary               




Figure 3 : The four most common plaque morphologies, based on a study of 42 patients with                
Coronary Artery Disease [9]. Types I-IV are characterized by a smooth protrusion, gradual             
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 3.2 Variables 
 
The variables referenced in the governing equations and boundary conditions are listed in Table 
1 along with their units and descriptions. The values used for the input parameters can be found 
in Table 2 of Section 3.6. 
 
Table 1:  Variables used in governing equations 
Symbol Unit Name/Description 
ρ  kg/m 3 Density of blood 
Dn  m 2 /s Diffusion coefficient of nanoparticle 
Dd,a  m 
2 /s Diffusion coefficient of drug in artery 
Dd,b  m 
2 /s Diffusion coefficient of drug in blood 
u  m/s Velocity of blood 
t  s Time 
cd  g/m 
3 Drug concentration 
cn  g/m 3 Nanoparticle concentration 
μ  Pa s·  Viscosity of blood 
P Pa Pressure of blood 
τ   Pa Shear stress in blood 
 
3.3 Governing Equations 
 
The flow was first simulated assuming a pulsatile inlet condition to more accurately model the               
system. Using the initial and boundary conditions specified in Figure 4, COMSOL could solve              
the Navier-Stokes and continuity equations in a time-dependent manner to determine the velocity             
profile, from which the shear gradient can be deduced: 
  
Conservation of momentum: 
𝑰( ·∇ū) P ·(μ(∇ū ∇ū) μ(∇·ū)ρ ∂t
∂ū + ū =  − ∇ + ∇ + ( T − 3
2 ) (1) 
 
Conservation of mass: 
·(ρū)∂t
∂ρ + ∇ = 0 (2) 
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 where  and u are the density and velocity of the fluid respectively.ρ  
 
The spread of nanoparticles and drug were modeled using the diffusion equation. 
 
Transport of nanoparticle: 
·(D ∇c ) ·(ūc )∂t
∂cn = ∇ n n − ∇ n + Gn (3) 
where is the diffusivity of nanoparticle in blood, u is the velocity due to natural Dn               
convection, and  is a conditional first order reaction term defined as:Gn  
 
f (τ )i  ≥ τ crit  
1000·cGn = − n  
lsee  
Gn = 0  
 
Transport of drug in blood: 
·(D ∇c ) ·(ūc )∂t
∂cd = ∇ d d − ∇ d + Gd  (4) 
 
where is the diffusivity of nitroglycerin in blood, u is the velocity due to natural Dd               
convection, and  is a conditional first order reaction term defined as:Gd  
 
f (τ )i  ≥ τ crit  
000·cGd = 1 n  
lsee  
Gd = 0  
 
Transport of drug in plaque: 
·(D ∇c )∂t
∂cd = ∇ d,p d (5) 
 
 
3.4 Boundary Conditions 
 
Inlet boundary conditions are applied at the top of the entire domain to maintain              
conservation of mass and to ensure that the fluid in the vessel is incompressible. Pressure at the                 
inlet and velocity at the outlet are defined by functions shown in Appendix A. Flux of the                 
velocity, nanoparticle, and drug are 0 at the axis of symmetry. Concentration of nanoparticle and               
drug at the outlet are 0. Concentration of nanoparticle at the inlet was implemented as a smooth                 
step function going from 0 to 0.1 in .1 secconds. Concentration of drug at the inlet is 0 as       m  g/ 3             
well. Velocity of the fluid is 0 at the vessel walls. Flux of nanoparticle and drug is 0 between all                    
subdomains. These boundary conditions are summarized in Figure 4. 
 




























Figure 4 : Schematic of the coronary artery as employed in the COMSOL model. Boundary              
conditions and initial conditions have been labeled for each of the three main physics. 
 
3.5 Initial Conditions 
 
There is no concentration of nanoparticle or drug in the artery at zero seconds.              
Furthermore, the initial fluid velocity in the domain is zero.  
∣  u t=o = 0 (6) 
∣  cn t=0 = 0 (7) 
∣cn z=0.08m = cn,in (8) 
∣  cd t=0 = 0 (9) 
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3.6 Input Parameters 
 
Constants and parameters derived from literature can be seen in Table 2. The pressure and               
velocity boundary conditions were obtained as experimental data from Armstrong et al., to             
generate pulsatile flow [2]. The graphs of these values can be seen in Appendix A. Input pressure                 
for pulsatile flow is a function of time given by data from Siogkas et al [10]. For stationary flow,                   
the inlet pressure is a constant 11549 Pa, equal to the average of the corresponding pulsatile flow                 
condition. Outlet velocity was similarly chosen as a pulsatile function of time, taken from data in                
Siogkas et al, with the outlet velocity for stationary flow being the average of 0.11375 m/s. The                 
diffusivity of nanoparticle in blood was chosen as that of PLGA, a common polymer from which                
nanoparticles are made [11]. Nitric oxide values were used for diffusivity of drug in blood and in                 
plaque [12][13]. Critical shear stress is taken from Korin et al. [1] Viscosity and density of blood                 
are commonly known values. Concentrations of nanoparticle and drug at the inlet were estimated              
from Korin et al [2]. 
Table 2: A list of input parameters used in this model 
Parameter Symbol Value Unit Source 
Pressure at inlet P  (t)P in  Pa [10] 
Outlet velocity u  (t)uout  m/s [10] 
Diffusivity of nanoparticle 
in blood 
Dn  1 10 -3·  µm 2 /s [11] 
Diffusivity of drug in blood Dd,b  3300 µm 
2 /s [12] 
Diffusivity of drug in 
plaque 
Dd,p  848 µm 
2 /s [13] 
Critical shear stress τ crit  10  Pa [1] 
Viscosity of blood μ  0.0032  Pa s·  [14] 
Density of blood ρ  1060 kg/m 3 [15] 
Concentration of 
nanoparticle at inlet 
cn,in  0.1 g/m 
3 N/A 
Concentration of drug at 
inlet 
cd  0 g/m 
3 N/A 
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 4. Results & Discussion 
4.1 Mesh 
 
To determine the element size for the mesh, a mesh convergence was performed as shown               
in  Appendix C . It was performed by calculating the volume integral of the velocity field in the                 
entire blood flow subdomain. It was found that the integral only changed by 1% by altering the                 
mesh from ‘fine’ to ‘extra fine’. All of the discrepancies in the mesh occured in the area around                  
the plaque. So, in order to make calculations more accurate, the area around the plaque was                
refined, as shown in  Figure 5 . This decreased discretization error in the areas where there are                
larger changes. The volume integral of drug concentration over the entire domain only changed              
by .15% from 3x to 4x refinement, therefore a “fine” mesh with 3x refinement over the region of                  
plaque was chosen for the model. This mesh can be seen in Figure 4. 
 
 
Figure 5: Mesh for fluid flow and transport of diluted species shown at the stenotic section of                 
the artery. The element size chosen in COMSOL for this mesh is “fine,” with a 3x refinement                 
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 4.2 Flow Characteristics 
 
The velocity profile in the blood vessel at various time points is shown in Figure 6. The                 
pulsating nature can be observed by the drastic changes in velocity magnitude over time. This               
profile agreed with the intuition that the velocity should have increased at the beginning of the                
plaque to satisfy continuity due to a smaller vessel diameter.  Total mass continuity can be used to                 
relate the fluid velocity to the cross-sectional area of the flow for incompressible fluids.              
Specifically, fluid velocity is inversely related to the cross-sectional area, meaning that the fluid              
velocity should increase where the cross-sectional area is decreasing, such as at the apex of the                
plaque. It can also be seen in Figure 6 that the profile becomes more homogeneous further down                 
the length of the vessel, where it eventually returns to a fully formed flow. 
 
 
Figure 6:  Velocity profile in the model at 0.76, 0.8, and 0.84 s. The velocity (m/s) is highest at                   
the center of the artery and lowest at the wall. It increases considerably in the area near the                  
constriction. The velocity magnitude varies in short amounts of time due to the pulsatile flow.  
 
The shear stress profile in the blood vessel at nine seconds is shown in Figure 7. O ne can                  
see the shear stress reaching a maximum value of around 100 Pa along the edge of the plaque,                  
upstream of the midpoint, where the constriction is increasing. A band of higher-than-average             
(but not maximum) shear stress can be seen continuing from that point down through the bottom                
of the frame. As defined, Newtonian flow has shear stresses which are linearly proportional to               
the velocity gradient at that point, where the constant of proportionality is the fluid’s viscosity.               
Since this model assumes incompressible, Newtonian flow, and since the viscosity is not             
changing, the magnitude of the shear stress at any point should be indicative of the magnitude of                 
the velocity gradient at that point. Along that cross-section, for fully-formed laminar flow the              
velocity profile should be parabolic which implies that the rate of change in the velocity should                
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 be decreasing as it approaches its inflection point (the axis of symmetry), where the rate of                
change in the velocity is zero. This profile explains why the shear stress decreases as one moves                 
toward the axis of symmetry where the velocity gradient is zero. To explain why the shear stress                 
is only higher than average upstream of the midpoint of the plaque, consider that an element of                 
fluid moving through the constriction will gain significant axial momentum while moving            
through the constriction. When the lumen widens downstream, it will require significant axial             
displacement before the smaller radial forces are able to re-attain fully formed flow by spreading               
this fast moving flow in the radial direction. This explains why the maximum shear stresses only                
occur on the upper half of the constriction and why the band of higher-than-average shear               
stresses continues a significant distance downstream from that point. Essentially, the fluid is             
moving so fast that is is unable to account for the rapid change in lumen diameter. It is important                   
to note that many points in this area exceed the critical shear stress of the nanoparticle, which is                  




Figure 7:  Shear stress profile in the model stenotic coronary artery. The highest shear stress               
occurs near the peak of the plaque formation. It can also be seen that a higher-than-average                
shear stress is present downstream of the plaque and closer to the center of the vessel.  
 
4.3 Short Term Nanoparticle Diffusion 
 
Diffusion of nanoparticle was coupled with fluid flow, simulated earlier. The           
concentration of the nanoparticles can be seen in Figure 8. The amount and profile of               
nanoparticles that breakdown vary with time as a result of the pulsatile flow. When the shear                
stress was generally higher, more nanoparticles were broken down as seen in Figure 8 at time                
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 1.36 seconds; when the shear stress is smaller in the blood, fewer nanoparticles overall were               
broken down and this occurred closer to the plaque as seen at time 1.7 seconds. 
 
Figure 8:  Nanoparticle concentration profile in blood of stenotic coronary artery for various time              
points. Nanoparticles were released closest to the point of greatest stenosis as expected. The              
concentration profile stays confined to a linear region close to the axis of symmetry as the plaque                 
declines. 
 
4.4 Short Term Drug Diffusion 
 
Diffusion of the drug was coupled with the earlier simulations of fluid flow and              
nanoparticle diffusion. The amount of drug released from the nanoparticle varies with time as a               
result of the pulsatile flow. It can be observed that initially the drug penetrates the plaque. As the                  
flow changes so does the the amount of drug released. Corresponding with Figure 8, more drug                
was released as more nanoparticle was broken down. As seen in Figure 9, more drug was                
released at time 1.36 seconds, while less was released at 1.7 seconds. 
 
 
14 of 26 
  
Figure 9:  Drug concentration profile in the blood of the model stenotic coronary artery for               
various time points. Drug generation is only present in areas of sufficient shear stress, which               
occurs by the plaque. At early times it can be seen that the drug only begins to penetrate the                   
plaque and diffuse into the tunica intima. 
 
4.5 Long Term Diffusion 
 
Due to computational constraints, it was not feasible to simulate pulsatile flow along with              
diffusion for long durations. Therefore, it was necessary to use steady flow for long term               
calculations. Using the longest pulsatile flow simulation, there was an observed difference of             
<0.5% in the amount of drug released between pulsatile flow and stationary flow models.              
Therefore, the stationary flow assumption was deemed acceptable for modeling long term drug             
delivery. Stationary flow was implemented using the average values of the pulsatile boundary             
conditions (pressure inlet and velocity outlet).  
A 30 minute simulation of nanoparticle transport is seen at several time points in Figure               
10. A steady stream of nanoparticles was observed near the center of the vessel after passing                
through the constriction. More importantly, one can see sections along the tissue side of the               
nanoparticle stream where one would intuitively expect nanoparticles but where none are            
present. These areas of low nanoparticle concentration approximately correspond to the areas            
where the shear stress is the highest. In a barely discernible section between the high and low                 
concentration areas, one can observe mid-range concentrations. This could be caused by partial             
breakdown of nanoparticles in those regions or by radial diffusion of the nanoparticles in the               
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 adjacent region. In any case, this effect is rapidly overcome by the influx of nanoparticles from                
upstream and by 80 seconds appears to reach a steady state. 
 
 
Figure 10: Long-term  nanoparticle concentration profile in model stenotic coronary artery over            
multiple time points. The nanoparticles breakdown close to the plaque in the constriction and              
remain in the center of the vessel as the blood flows. 
 
Drug diffusion shows results which are practically complementary to the long-term           
nanoparticle diffusion simulations. This is expected, since drug is generated only where            
nanoparticle is destroyed which occurs in areas where shear stress is higher than average. Most               
drug is released just before the plaque reaches its maximum thickness, as shown in Figure 11 and                 
the concentrations downstream are mainly due to transport from that area as opposed to              
generation in that location. Though most drug is released before the narrowest section of the               
vessel, convection significantly outweighs diffusion due to the high blood velocity. As a result,              
most drug is transported downstream and diffuses into the arterial walls unaffected by plaque. By               
1800 seconds the drug reaches a significant concentration within the plaque.  
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Figure 11:  Drug concentration profiles in model stenotic coronary artery for multiple time             
points. Most of the drug is released near the plaque. However, much of it is transported                




To check the model’s validity, a literature search was performed on characterizations of             
obstructed coronary arteries. The accuracy of the velocity data from the COMSOL model was              
validated using the Ofili et. al. paper characterizing the blood flow in coronary arteries. The               
mean velocity in the paper for the coronary arteries measured for healthy patients varied from 0.2                
to 0.3 m/s as compared to the average velocity measured in this study of 0.18 m/s measured at                  
the thickest portion of the plaque [16]. An additional emphasis was placed on validating the               
shear stress profile, since the shear stress is what determines whether or not nanoparticles release               
drug. 
The accuracy of the shear stress data from the COMSOL model can be validated by a                
1993 study of hemodynamic factors in a stenotic right coronary artery as seen in Figure 12.                
Shear stress at the center of stenosis ranged between 50-200 Pa over 18 trials, with an average of                  
135 Pa. This is close to the computed value of 115 Pa [17]. 
 
17 of 26 
  
 
Figure 12:  Average  Shear Stress profile for 18 different trials. Shear stress drastically increases              
nearest to where the plaque begins. It gradually declines due to a smooth plaque morphology               
[17]. 
4.7 Sensitivity Analysis 
 
Four input parameters were tested for the sensitivity analysis: particle critical stress, the             
initial nanoparticle concentration, and the diffusion coefficient of the drug in the blood and              
plaque. Each parameter was varied by  ± 20%. The effect of these changes was observed by                
taking the integral of drug concentration over the entire domain and comparing the relative              
difference. The integral was most sensitive to changes in the concentration and critical particle              
stress and very insensitive to the diffusivity in the blood and plaque. From a treatment               
standpoint, only initial nanoparticle concentration and the critical particles shear stress can be             
manipulated. 
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 Figure 13: Sensitivity analysis of drug concentration over entire domain (fluid, plaque, and             
tissue) with varying diffusivities, inlet drug concentrations, and nanoparticle critical stress. From            
this analysis, the most influential parameters were found to be the critical shear stress of the                
particle, and the concentration of the nanoparticle at the inlet of the vessel. 
4.8 Optimization 
 
The objective function was applied to two parameters: the critical shear stress and the              
nanoparticle perfusion concentration because these are the two parameters that can realistically            
be controlled when designing a nanoparticle carrier. The following concentration flow rate            
constraints were used to formulate an optimization function [2]. 
 
5 μg min  ṁno,min =  /
00 μg min  ṁno,max = 5 /
 
These yielded the following optimization function: 
(c (t)) (c (t)) (c (t))L i = ∑
n
i
drug,plaque,i / drug,out,i (6) 
 
The optimization showed a higher critical stress for the nanoparticle until it exceeded 75              
Pa. This result is expected since having a higher critical stress means the nanoparticle will not                
breakdown until it is closer to the wall. However, this also results in less drug getting released                 
overall. The optimal value of 75 Pa was close to the highest recorded shear stress in our                 
stationary flow model. Therefore when the critical shear stress of the nanoparticle was above 75               
Pa no drug was released. 
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Figure 14: Optimization objective gain function was applied to determine the optimum critical             
shear stress of the nanoparticle for maximum drug diffusion into the arterial wall and minimum               
amount of drug flowing out of the vessel. The optimum critical shear stress was found to be 75                  
Pa. 
 
Next the nanoparticle inlet concentration was optimized. The range for the objective            
function for nanoparticle perfusion is between 5.7ׂ8 10 -4 mol/m 3 and 0.046 mol/m 3 . The      ·       
function seems to achieve similar maxima at several different perfusion concentrations.           
However, based on current clinical guidelines for the administration of nitroglycerin, maximum            
allowable amount of nitroglycerin infused is about, .05 mol/m 3 . So we chose the maximum of               
0.045 mol/m 3  to be under the maximum allowable dosage in case all nanoparticles were to               
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 Figure 15:  The objective gain function was applied to find the nanoparticle inlet concentration              
that maximizes drug diffusion into the arterial wall while minimizing drug remaining in the              
blood. The optimum inlet concentration was chosen to stay within recommended clinical            
maximum of  0.5 mol/m 3 . 
 
5. Conclusion & Design Recommendations 
 
The model demonstrates that shear stress-induced nanoparticle drug delivery for          
treatment of coronary artery disease may not be as effective as imagined since little to no drug                 
diffused into the artery wall upstream of the plaque apex. The effectiveness of this method is                
certainly dependent on the encapsulated drug as well as the disease severity and other individual               
variations. This study showed that the specificity of this method can be improved by simple               
optimization of the critical shear stress and inlet concentration of the nanoparticle. However,             
even with optimization the process still delivers almost all of the drug downstream of the plaque                
apex. Therefore shear stress sensitive nanoparticles do not appear to optimally deliver            
nitroglycerin to coronary artery stenoses. However, clinical experiments must be performed to            
accurately evaluate the effectiveness of this method. 
For further investigation, it is important to look at the effect of treatment on other plaque                
morphologies and in other blood vessels as well as on a realistic 3D geometry, with               
non-newtonian flow, or even with artery dilation in response to drug release. It is expected that                
this method will perform better in type III plaque morphologies where the greatest constriction              
occurs at the beginning of the plaque, allowing a full plaque length for drug diffusion as opposed                 
to only a half plaque length. It would also be important look at the release of the drug in                   
capillaries where shear stresses may also be high. While this may not be an effective means of                 
targeted drug delivery for coronary artery disease, shear stress induced nanoparticles could            
potentially be useful in other diseases. For example, it has been shown that fluid shear stress                
activates YAP1, which affects cancer cell motility [18]. This method could be used as a means of                 




We would like to thank Professor Ashim Datta for his support and guidance, Mayuri Ukidwe for                
her dedication and COMSOL advice, and Dr. Rick Evans and Dr. Traci Nathans-Kelly for              




21 of 26 
  
 
Appendix A: Mathematical Model 
  
Pulsatile Flow Pressure and Velocity Profiles  
 
A periodic pressure function, as shown in the figure below, was used to describe the pressure                
boundary condition at the inlet for pulsatile flow. 
 
 
Figure 16. The inlet pressure boundary condition for pulsatile blood flow shown over 3 periods.               
Pressure oscillates approximately between 8000-16000 Pa [10]. 
 
A periodic velocity function, as shown in the figure below, was used to describe the velocity                
boundary condition at the outlet for pulsatile flow. 
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Figure 17. The outlet velocity boundary condition shown over 3 periods. It oscillates             
approximately between 0.05 and 0.2 m/s [10].  
 
Appendix B: Solution Strategy 
 
The calculation time took approximately 3 hours and 2GB memory. The PARADISO Solver was              
used by default and there was no reason to change it. Time stepping was free by default and did                   





To ensure that discretization error was minimized a mesh convergence was performed on both              
velocity and drug concentration as can be seen in Figures 18 and 19, respectively. The integral of                 
the values over the domain was calculated, which give more accurate values rather than only               
calculating the value at a given point.  
 
 
23 of 26 
  
Figure 18:  Mesh Convergence using the integral of the velocity over the entire vessel domain at                
two seconds. One was done by changing the mesh for the entire structure from coarse to extra                 
fine. The other was performed by setting the entire mesh to fine and refining the area containing                 
plaque. Marginal changes can be seen after a refinement of x2 by the plaque. 
 
Figure 19:  Mesh Convergence using the integral of the drug concentration over the entire vessel               
domain at two seconds. The entire mesh is fine and the area containing plaque was increasingly                
refined. Marginal changes can be seen after a refinement of x3 by the plaque. 
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